Q51130732
Dotaz
Zobrazit nápovědu
Differential pulse voltammetry, direct current voltammetry, adsorptive stripping voltammetry and HPLC with electrochemical detection were used for the determination of 5-amino-6-nitroquinoline at a carbon paste electrode. The methods are based either on anodic oxidation or cathodic reduction of this substance, whose electrochemical behavior at carbon paste electrode was further studied by cyclic voltammetry. Practical applicability of these methods was demonstrated on the determination of 5-amino-6-nitroquinoline in model samples of drinking and river water. The detection limit was 2.0 × 10–6 mol l–1 for anodic differential pulse voltammetry in a mixture of Britton–Robinson buffer (pH 11)–methanol 1:1 (v/v) and 1.6 × 10–7 mol l–1 for HPLC with electrochemical detection (E = +1.2 V) in a mobile phase Britton–Robinson buffer (pH 7)–methanol 1:9 (v/v).
Direct current voltammetric (DCV) and differential pulse voltammetric (DPV) determination of antineoplastic agent doxorubicin (DOX) at a carbon paste electrode (CPE) was developed. Britton–Robinson buffer (pH 7.0) was used as a supporting electrolyte. The limits of detection are 8 × 10–7 mol l–1 (DCV) and 6 × 10–8 mol l–1 (DPV). The accumulation of DOX at the electrode surface was used to decrease the limits of detection down to 2.2 × 10–7 mol l–1 for adsorptive stripping DC voltammetry (DCAdSV) and 2.8 × 10–9 mol l–1 for adsorptive stripping differential pulse voltammetry (DPAdSV) at CPE. The results of the voltammetric methods were utilized for the development of a new determination of doxorubicin using HPLC with amperometric detection on CPE based on spherical microparticles of glassy carbon in a wall-jet configuration. A column with chemically bonded C18 stationary phase and a mobile phase containing 0.01 M phosphate buffer (pH 5.0)–methanol 25:75 (v/v) were used. The limit of detection is 4 × 10–7 mol l–1 (HPLC with electrochemical detection (ED)).
Je podán přehled metod likvidace vybraných protinádorových léčiv s možným genotoxickým působením na pracovníky, kteří jsou těmto látkám vystaveni během jejich přípravy, při podávání pacientům, či jsou v kontaktu s kontaminovaným odpadem. Tyto metody, které byly vypracovány a ověřeny v rámci projektů IARC, na nichž se podílela i naše pracoviště, jsou použitelné pro likvidaci následujících protinádorových léčiv: amsacrin, azathioprin, carmustin, chlorozotocin, cis-platina, cyklofosfamid, daunorubicin, dichlormethotrexat, doxorubicin, ifosfamid, lomustin, melphalan, 6-merkaptopurin, methotrexat, semustin, streptozotocin, 6-thioguanin, thiotepa, vincristin, vinblastin. Při jejich rozšíření na strukturně příbuzná protinádorová léčiva je třeba vždy předem ověřit jejich chemickou i biologickou účinnost.
Methods suitable for the decontamination and destruction of selected anti-cancer drugs with possible genotoxic effects on hospital staff coming into contact with those drugs during their preparation, application or during contact with contaminated hospital wastes have been reviewed. These methods, developed in co-operation with our laboratories and verified by International Agency for Research on Cancer, are applicable to the following anti-cancer drugs: amsacrine, azathioprine, carmustine, chlorozotocine, cis-platin, cyclofosfamide, daunorubicin, dichlormethotrexat, doxorubicin, ifosfamid, lomustine, melphalan, 6-merkaptopurine, methotrexat, semustine, streptozotocine, 6-thioguanine, thiotepa, vincristine, and vinblastine. For their application on structurally similar anti-cancer drugs, it is necessary to first verify their chemical and biological effectiveness.
